Head-to-Head Comparison: Personalis (NASDAQ:PSNL) vs. BioNexus Gene Lab (NASDAQ:BGLC)

BioNexus Gene Lab ( NASDAQ:BGLC – Get Your Free Report ) and Personalis ( NASDAQ:PSNL – Get Your Free Report ) are both small-cap medical companies, but which is the superior business? We’ll compare the two companies based on dividend strength, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

return

This table compares BioNexus Gene Lab and Personalis’ net margins, return on equity and return on assets.

Earnings and Rating

This table compares BioNexus Gene Lab and Personalis’ gross revenue, earnings per share and valuation.

BioNexus Gene Lab has higher revenue, but lower revenue than Personalis.

Analyst ratings

This is a breakdown of current ratings and price targets for BioNexus Gene Lab and Personalis as provided by MarketBeat.com.

Personalis has a consensus target price of $6.81, indicating a potential upside of 37.90%. Given Personalis’ higher probable upside, analysts plainly believe Personalis is more favorable than BioNexus Gene Lab.

Volatility and risk

BioNexus Gene Lab has a beta of 7.78, suggesting its share price is 678% more volatile than the S&P 500. Comparatively, Personalis has a beta of 1.92, suggesting its share price is 92% more volatile than the S&P 500. more volatile than the S&P 500.

Insider and institutional ownership

18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 61.9% of Personalis shares are held by institutional investors. 6.8% of BioNexus Gene Lab shares are owned by insiders. Comparatively, 4.1% of Personalis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and big money managers believe the stock is poised for long-term growth.

Summary

BioNexus Gene Lab beats Personalis on 6 of the 11 factors compared between the two stocks.

About BioNexus Gene Lab

(Get a free report)

BioNexus Gene Lab Corp., through its subsidiary, sells chemical products from raw materials in Malaysia, Indonesia, Vietnam and other Southeast Asian countries. The company offers feedstock chemicals that include polyester resin SHCP 268, a thixotropic, fast-curing unsaturated polyester resin suitable as a general purpose resin; Polyester resin 9509, a general purpose material used in the production of marine boats and water slides; and 2802 polyester resin used as a component in the pultrusion process by certain manufacturers. Its products are used to produce railings, bench tops, automotive and aero parts, and paneling for hospitals, laboratories, industrial clean rooms and covers for various tools used in manufacturing. The company is also involved in the development and provision of non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential disease risk. It markets its products through its website, warehouse, marketing staff and suppliers. The company was established in 2017 and is headquartered in Kuala Lumpur, Malaysia.

About Personalis

(Get a free report)

Personalis, Inc. develops and markets advanced cancer genomic tests and analyses, primarily in the United States, Europe and Asia-Pacific. Its tests and analyzes are used by pharmaceutical companies for translational research, biomarker discovery and the development of personalized cancer therapies, and advanced tests are used by doctors to detect cancer recurrence, monitor cancer progression and discover insights for therapy selection . The company offers NeXT Personal, a tumor-based liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based assay that combines whole-exome (DNA) and whole-transcriptome (RNA) sequencing data with advanced analytics to provide a multidimensional view of the tumor and tumor microenvironment from a single sample. It also offers NeXT Personal Dx, a tumor-based liquid biopsy test for detecting MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling assay that unlocks the entire exome (DNA) and transcriptome (RNA) with normal tumor correlated analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and blood samples suitable for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects such as population sequencing initiatives, as well as sequencing and data analysis services to support population sequencing initiatives. His clients include pharmaceutical companies, biopharmaceutical companies, diagnostic companies, universities, non-profit organizations, government entities and patients. The company was founded in 2011 and is headquartered in Fremont, California.

Get news and reviews for BioNexus Gene Lab Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioNexus Gene Lab and related companies with MarketBeat.com’s FREE daily email newsletter.